User:Anjan K Chakrabarti

Jump to navigation Jump to search
Anjan K Chakrabarti, M.D.

Anjan K. Chakrabarti M.D., Cardiovascular Disease Fellow, Beth Israel Deaconess Medical Center, Harvard Medical School

Executive Editor, WikiDoc Foundation (a 509 (a)(1) Charitable Organization)

Contact:; Phone 617-632-7828

Mailing Address: Anjan K. Chakrbarti M.D., 185 Pilgrim Road, Baker 4, Boston MA, 02215.


Anjan K. Chakrabati, M.D., is currently a Cardiovascular Disease Fellow with the Harvard Medical School at Beth Israel Deaconess Medical Center. His primary clinical interests are in General Cardiology and Interventional Cardiology. His research focus to this point has been on clinical outcomes in acute coronary syndromes; he was able to work with leaders in this field during my time at the University of Michigan and publish his work as first author in the Journal of the American College of Cardiology. Currently, in addition to his clinical training, he is an active investigator in multiple clinical trials with his research mentor, Dr. C Michael Gibson. He also has served as a reviewer for prominent journal such as Journal of the American College of Cardiology, Critical Pathways in Cardiology, European Heart Journal, and Platelets.

His prior research experience included translational research in the field of Vascular Medicine; specifically, he assessed genetic polymorphisms and their effect on endothelial function measured by brachial artery reactivity and was co-author on a number of publications in peer-reviewed journals on this topic.

His contributions to teaching and education have primary consisted of informal teaching of medical students and residents during post-graduate training. During his year as a Clinical Lecturer at the University of Michigan he was able to directly supervise and teach residents and students both in the Urgent Care/Emergency Department setting as well as the General Medicine Wards. As a Cardiovascular Disease Fellow he regularly participates in formal clinical conferences highlighting fundamental and advanced principles of cardiovascular medicine and formally supervise residents in the Cardiac Intensive Care Unit and Inpatient Cardiology Wards.

A significant portion of his time has been devoted to community projects and committees of the major medical organizations. While a resident of Detroit he worked with outreach groups including Habitat for Humanity, Code Blue, ARIE, and Teach Peace. In addition, he has spent a significant portion of time during his post-graduate training and beyond working with free and low-income community clinics, including the Cass Clinic and HOPE clinic. He was able to represent the University of Michigan and develop institutional ties with Korle Bu Hospital in Accra, Ghana while spending a month practicing clinical medicine with limited resources.

During his fellowship he aims to continue my clinical development in General and Interventional Cardiology, be productive with research, and pursue formal training in clinical research and biostatistics.


Peer reviewed publications in print or other media

  1. Shamim-Uzzaman Q, Pfenninger D, Kehrer C, Chakrabarti A, Kacirotti N, Rubenfire M, Brook R, Rajagopalan S. Altered Cutaneous Microvascular Responses to Reactive Hyperemia is Predictive of Coronary Artery Disease: A Comparative Study With Conduit Vessel Responses. Clinical Science. 2002 Sep;103(3): 267–273.
  2. Duquaine D, Hirsch GA, Chakrabarti A, Han Z, Kehrer C, Brook R, Joseph J, Schott A,bKalyanaraman B, Vasquez-Vivar J, Rajagopalan S. Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase. Vascular Medicine. 2003 May;8(2): 101-7.
  3. Schmidt MA, Chakrabarti A, Shamim-Uzzaman Q, Kaciroti N, Koeppe RA, Rajagopalan S. Calf flow reserve with H(2)(15)O PET as a quantifiable index of lower extremity flow. Journal of Nuclear Medicine. 2003 Jun;44(6): 915-9.
  4. Rajagopalan S, Pfenninger D, Kehrer C, Chakrabarti A, Somers E, Pavlic R, Mukherjee D, Brook R, D'Alecy LG, Kaplan MJ. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. Arthritis & Rheumatism. 2003 Jul;48(7): 1992-2000.
  5. Schmidt, M, Chakrabarti A, Kehrer C, Pfeninger D, Brooke R, Kacorati N, Duvernoy C, Killeen A, Rajagopalan S. Interactive Effects of the ACE DD Polymorphism With the NOS III Homozygous G849T (Glu298-Asp) Variant in Determining Endothelial Function in Coronary Artery Disease. Vascular Medicine. 2003 Aug 3; 8(3): 177-183.
  6. Rajagopalan S, Pfenninger D, Somers E, Kehrer C, Chakrabarti A, Mukherjee D, Brook R, Kaplan MJ. Effects of cilostazol in patients with Raynaud's syndrome. American Journal of Cardiology. 2003 Dec 1;92(11): 1310-5.
  7. Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, Chakrabarti A, Richardson BC, Shelden E, McCune WJ, Kaplan MJ. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004 May 15;103(10): 3677-83.
  8. Chakrabarti A, Krumholz HM, Wang Y, Rumsfeld JS, Nallamothu BK; National Cardiovascular Data Registry. Time-to-reperfusion in patients undergoing interhospital transfer for primary percutaneous coronary intervention in the U.S: an analysis of 2005 and 2006 data from the National Cardiovascular Data Registry. J Am Coll Cardiol. 2008 Jun 24;51(25): 2442-3.


  1. Chakrabarti AK, Gibson CM. Short- and long-term treatment with non-steroidal anti-inflammatory drugs increases risk of death or recurrent MI in those with previous MI. Evid Based Med 2011;ebmed-2011-100132Published Online First: 21 September 2011 doi:10.1136/ebm.2011.100132

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

  1. “Production of Albumin-Coated Dodecaflouropentane Droplets for Ultrasonic Imaging and Cancer Treatment.” Presented at the University of Michigan UROP Presentation, Ann Arbor, MI, May 2000.
  2. “Interactive Effects of a Common NOS III Polymorphism with ACE Genotype on Endothelial Function.” Presented at the University of Michigan 10th Annual Department of Internal Medicine Research Symposium, Ann Arbor, MI, May 11, 2002.
  3. “PET Derived Flow Reserve: Validation in Subjects with PAD.” Presented at the Society for Vascular Medicine and Biology 13th Annual Meeting, Boston, MA, June 7-9, 2002.
  4. “Interactive Effects of the ACE DD Polymorphism With the NOS III Homozygous G849T (Glu298-Asp) Variant in Determining Endothelial Function in Coronary Artery Disease.” Presented at the American College of Cardiology 52nd Annual Scientific Meeting, Chicago, IL, March 30-April 2, 2003.
  5. “STAT Lab Orders: Protecting Patients’ Interests.” Presented at the Internal Medicine Residency Program Patient Safety Symposium, Ann Arbor, MI, June 12, 2008.
  6. “An Unusual Presentation of a Rare Disorder: Sweet’s Syndrome.” Presented at the American College of Physicians Michigan Chapter Annual Scientific Meeting, Dearborn, MI, September 11, 2008. 1st Place for Case Report Poster Presentation.

Invited Presentations and Courses

  1. “TandemHeartTM Circulatory Assistance in Bi-Ventricular Failure.” Presented at the Massachusetts Chapter American College of Cardiology 2010 Annual Meeting, Waltham, MA, December 17-18, 2010. Selected for ACC Scholarship Award.